Physician profile
Andrew Riggin
NPI 1780941492
$3,763.86
in general payments reported to CMS, 2019-2025
30 companies · $623 in 2025
The $623 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $75.12 · 2021: $92.78 · 2022: $724 · 2023: $1,193 · 2024: $713 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.50 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $955.33 | 2019-2025 | Naviguide, Lithoclast, Ams 700 |
| Dornier Medtech America, INC | $389.32 | 2023 | Dornier Medtech |
| Janssen Biotech, INC. | $304.22 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $279.00 | 2023-2025 | |
| Abbvie INC. | $272.73 | 2023-2025 | Botox, Lupron Depot |
| Sumitomo Pharma America, INC. | $190.20 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $159.36 | 2019-2024 | Xtandi, Veozah, Myrbetriq |
| Pfizer INC. | $118.73 | 2019-2024 | |
| Coloplast Corp | $114.18 | 2019-2025 | |
| Progenics Pharmaceuticals, INC. | $111.28 | 2024-2025 | |
| Tolmar, INC. | $99.30 | 2023-2024 | |
| Telix Pharmaceuticals | $96.05 | 2023 | Illuccix |
| Dendreon Pharmaceuticals LLC | $94.48 | 2019-2023 | Provenge |
| Olympus America INC. | $90.73 | 2019-2024 | Itind System |
| Merck Sharp & Dohme LLC | $66.96 | 2022-2024 | Keytruda, Lynparza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis, INC | $49.33 | 2021 | |
| Baxter Healthcare | $43.81 | 2023 | Tisseel |
| Ferring Pharmaceuticals INC. | $40.14 | 2024 | Adstiladrin |
| Endo Pharmaceuticals INC. | $39.80 | 2020-2022 | |
| Endo USA, INC. | $36.63 | 2024 | Aveed, Xiaflex |
| Karl Storz Endoscopy-America | $29.48 | 2024 | Hopkins |
| Neotract INC. | $25.98 | 2020 | |
| Immunitybio, INC. | $24.38 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $24.00 | 2019 | |
| Urogen Pharma, INC. | $23.35 | 2025 | |
| Teleflex LLC | $19.10 | 2022 | |
| Supreme Orthopedic Systems, LLC | $17.21 | 2023 | |
| Photocure INC | $17.18 | 2025 | Cysview |
| Procept Biorobotics Corporation | $16.09 | 2023 | Aquabeam Robotic System |
| Stryker Corporation | $15.51 | 2024 | 1788 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Riggin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.